CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
IV Magnesium Sulfate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06603766
NCT06603766Phase 3Completed
CompareCT.gov

Comparative Study Between Nebuliezed and Intravenous Magnesium Sulfate for Treatment of Persistant Pulmonary Hypertension in Neonates

Benha University·interventional·Posted Sep 19, 2024·Updated Feb 5, 2025

In Brief

A Phase 3 clinical trial evaluating IV Magnesium Sulfate and Inhalational magnesium sulfate for Magnesium Sulfate - PPHN. Completed, enrolled 40 participants across 1 site.

Detailed Summary

we conducted this study to compare between effect of nebulized and intravenous magnesium sulfate (MgSO₄) for better treatment of persistent pulmonary hypertension of neonates with less side effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMagnesium Sulfate - PPHN
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedSep 19, 2024
Enrollment StartOct 1, 2021
Primary CompletionSep 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 1.8 years ago

Interventions

IV Magnesium Sulfatedrug

MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.

Inhalational magnesium sulfatedrug

It gives us the same mechanism of action as IV MgSO4 with less side effects.